In this first of two podcasts, an expert discusses the data supporting their selection of first-line treatments for advanced gastric cancer. A case illustrates key takeaways about molecular markers that can impact choice of therapy in gastric cancer, novel and emerging treatments, and prevention and management of treatment-related toxicities. This activity is available for CE/CME credit. Claim your credit at pce.is/GIGU.

Contributor:

David Ilson, MD

Dr Ilson: consulting fees: Aeris, Amgen, Astellas, AstraZeneca, Bayer, Bristol-Myers Squibb, Lilly, Merck, Roche, Taiho.